Educational content only. Not medical advice. Consult a qualified physician.
Selank peptide
CognitiveApproved in Russia as a pharmaceutical for anxiety. Not FDA-approved in the United States. Available as a research compound in the West.

Selank

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the naturally occurring immunomodulatory peptide tuftsin with an added Pro-Gly-Pro sequence for stability. It is approved in Russia as an anxiolytic and nootropic nasal spray.
Reported Benefits

Potential Benefits

  • Approved in Russia for anxiety and generalized anxiety disorder
  • Research suggests anxiolytic effects without sedation or cognitive impairment
  • Studies indicate potential nootropic properties, including improved memory and learning
  • May modulate the immune system through effects on cytokine expression
  • Preclinical data suggests potential influence on BDNF expression
  • Does not appear to carry addiction or tolerance risk based on available data
Research Dosing

Recommended Starting Dose

250-500 mcg intranasally per dose

Based on published research protocols. Not a prescription.

Dosing Protocol

Typically administered as a nasal spray at 250-500 mcg per dose, 2-3 times daily. Treatment courses in Russian clinical practice run 14 days, with the option to repeat after a break. Some protocols use subcutaneous injection at similar doses.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Anxiolytic effects are often reported within the first few days of use. Cognitive benefits may develop over 1-2 weeks of consistent administration.

Regulatory

Research Status

Approved in Russia as a pharmaceutical for anxiety. Not FDA-approved in the United States. Available as a research compound in the West.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Generally well-tolerated in clinical settings
  • Nasal irritation with intranasal administration
  • Mild fatigue in some reports
  • Limited long-term safety data outside Russian studies
  • Potential interactions with other anxiolytic or psychoactive substances
Related Research

More in Cognitive

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.